The US Food and Drug Administration is questioning whether ocular toxicity with GlaxoSmithKline plc’s belantamab mafodotin outweighs the drug’s benefits in relapsed/refractory multiple myeloma.
US FDA Eyes Ocular Risks With GlaxoSmithKline’s Myeloma Drug Belantamab
Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.
More from US FDA Performance Tracker
More from Regulatory Trackers
• By
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
• By
March features nearly 20 user fee goal dates, including a crowd of novel candidates for crowded areas like hemophilia, heart disease and urinary tract infections, as well as the potentially first therapies for a rare eye disease and hyperphagia of Prader-Willi syndrome.
• By
The European Medicines Agency is set to issue opinions this week on whether pan-EU marketing approval should be granted to a number of new products.